GlassScriptPhysician profile
Andrew Patchett
NPI 1235423518
$3,279.18
in general payments reported to CMS, 2019-2025
28 companies · $539 in 2025
The $539 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $78.11 · 2021: $310 · 2022: $392 · 2023: $709 · 2024: $492 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,740.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $378.07 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $357.40 | 2019-2025 | |
| Amgen INC. | $312.32 | 2019-2025 | Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $253.16 | 2019-2025 | Lokelma, Farxiga, Evusheld |
| Genentech USA, INC. | $251.04 | 2019 | |
| Mallinckrodt Hospital Products INC. | $188.46 | 2021-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $187.23 | 2019-2025 | Ultomiris |
| Vifor Pharma, INC. | $163.90 | 2019-2025 | Veltassa, Korsuva |
| Opko Pharmaceuticals, LLC | $154.83 | 2019-2024 | Rayaldee |
| Glaxosmithkline, LLC. | $149.84 | 2020-2025 | Benlysta, Nucala |
| Horizon Therapeutics Plc | $138.59 | 2019-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $127.21 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $115.57 | 2024-2025 | Tarpeyo |
| Daiichi Sankyo INC. | $81.32 | 2022-2023 | Injectafer |
| Ardelyx, INC. | $52.50 | 2024 | Ibsrela |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $46.85 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.67 | 2020-2023 | Gattex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.47 | 2021-2022 | |
| Genzyme Corporation | $35.94 | 2019 | |
| Fresenius USA Marketing, INC. | $34.86 | 2023 | |
| Baxter Healthcare | $30.66 | 2022-2023 | Renal - Extraneal Solution |
| Regeneron Healthcare Solutions, INC. | $26.05 | 2019 | |
| Lilly USA, LLC | $20.97 | 2024 | Jardiance |
| Mallinckrodt Enterprises LLC | $20.96 | 2019 | |
| Alnylam Pharmaceuticals INC. | $19.53 | 2023 | Oxlumo |
| Bard Peripheral Vascular, INC. | $18.36 | 2023 | Wavelinq |
| Shire North American Group INC | $15.91 | 2019 | |
| Cormedix INC. | $15.51 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Patchett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.